The use of topoisomerase I inhibitors in multiple myeloma.

The standard treatment of multiple myeloma is systemic chemotherapy. Despite 30 years of drug development in myeloma, there are no new drug regimens significantly superior to melphalan and prednisone. In addition, phase II studies of new drugs in myeloma have been disappointing, with low response rates and no prolongation in survival. The topoisomerase I (topo […]

DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide.

The nuclear enzyme DNA topoisomerase II (topo II) is the target of important antitumor agents such as etoposide. Recent work has classified topo II targeting drugs into either topo II poisons that act by stabilizing enzyme-DNA cleavable complexes leading to DNA breaks, or topo II catalytic inhibitors that act at stages in the catalytic cycle […]

Biological targets of antitumor indolocarbazoles bearing a sugar moiety..

Natural and synthetic indolocarbazole compounds have triggered considerable interest since the discovery in 1986 of the inhibitory properties of staurosporine toward protein kinase C (PKC). Later, it has been shown that indolocarbazole compounds may inhibit various kinases, such as cyclin dependent-kinases and/or topoisomerase I, someones behave only as DNA intercalators. In this review are presented […]

Contract R&D to Identify Drugs that Target Human Topo I, Topo II, Bacterial Topo IV and DNA Gyrase

Experience. Rapid Turn-Around. Publication Quality. TopoGEN has >20 yrs. experience in the area as a Contract Research Organization and we stand behind our results. We guarantee clear, cosmetic data and unambiguous interpretations. You will receive a publication quality product. We are seasoned veterans in the arena of in vitro testing. More importantly, we can help […]

0
    0
    Your Cart
    Your cart is emptyReturn to Shop